Administration of phospholipide hepatoprotective drug Phosphogliv in patients with psoriatic arthritis (preliminary results)

Considering membrane-reparative properties of a new phospholipid hepatoprotector Phosphogliv (FG) its therapeutic efficacy was assessed in 9 pts with psoriatic arthritis (PA) accompanied by prominent disturbances of blood rheology. FG was given 0,6 g a day during 3 months. Significant decrease of er...

Full description

Saved in:
Bibliographic Details
Main Authors: T. V. Korotaeva, E. L. Nassonov, O. M. Ipatova, N N Firsov, O A Fvkina, TA Torhovskaya, A. I. Archakov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2004-06-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/1307
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Considering membrane-reparative properties of a new phospholipid hepatoprotector Phosphogliv (FG) its therapeutic efficacy was assessed in 9 pts with psoriatic arthritis (PA) accompanied by prominent disturbances of blood rheology. FG was given 0,6 g a day during 3 months. Significant decrease of erythrocyte aggregation resulting in increase of erythrocyte aggregation formation time and diminishment of their hydrodynamic resistance without changes of whole blood general caisson viscosity was achieved. Significant improvement of Richie index, tender joint count and pt assessment was noted. The results prove availability of PG administration in PA therapy and possibility of enlargement PG application area owing to membrane-reparative properties of contained in it polyunsaturated phosphatidilcholin in combination with immunomodulating and anti-inflammatory action of glycyrrhizinic acid.
ISSN:1995-4484
1995-4492